Treatment Algorithm for Limited-Stage Small Cell Lung Cancer

Real-world atezolizumab plus chemotherapy data demonstrated similar efficacy compared with what the phase 3 IMpower133 trial showed.

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Pooled analysis data support atezolizumab continuation as a viable second-line therapy option in extensive-stage small cell lung cancer.

Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.

Support for the recommendation is based on phase 3 ADRIATIC trial results showing a 27% reduction in the risk of death with durvalumab vs placebo.

A phase 1a/1b trial showed that ZL-1310 elicited an ORR of 74%, all of which were PRs, in patients with SCLC who received prior chemotherapy.